Department of Pediatrics, School of Medicine, Namazi Teaching Hospital, Abu Ali Sina for Medicine & Organ Transplant, Shiraz University of Medical Sciences, Mashhad, Iran.
Pediatric Gastroenterology and Hepatology Research Center, Zabol University of Medical Sciences, Zabol, Iran.
Hum Antibodies. 2022;30(4):183-194. doi: 10.3233/HAB-220016.
One of the most severe side effects of solid-organ transplantation is posttransplant lymphoproliferative disease (PTLD). People with human immunodeficiency virus infection (HIV), an immunosuppressive disease comparable to HIV, have a higher chance of developing lymphoma when their peripheral blood contains elevated levels of the immunoglobulins kappa and lambda free light chains (FLCs).
This systematic review's objective was to monitor associated B lymphoma cells in PTLD patients. In order to find relevant studies published between 1/1/2000 and 1/9/2022, two independent researchers conducted searches (MT, AJ). A literature search of English language publications was conducted using MEDLINE through PubMed, EMBASETM through Ovid, the Cochrane Library, and Trip. In addition to Magiran and SID, we searched KoreaMed and LILACS for literature published in other languages. sFLC or PTLD, transplant, or Electrophoresis are terms used in the search strategy.
A total of 174 studies were selected. After analyzing their correspondence with the required criteria, a final review of five studies was conducted. The manuscript presents current findings on the potential benefits of the clinical applicability of sFLCs in PTLD. While the preliminary results appear promising, the only consistent result is that early-onset PTLD is predicted within the first two years after transplant, a biomarker that could be used to diagnose the condition.
Therefore, PTLD has been predicted by using the sFLCs. There have been contradictory results to date. Future research could include assessing the quantity of sFLCs and their quality in transplant recipients. In addition to PTLD and complications after transplantation, sFLCs may provide insight into other diseases. To confirm the validity of sFLCs, more studies are needed.
实体器官移植后最严重的副作用之一是移植后淋巴组织增生性疾病（PTLD）。患有人类免疫缺陷病毒感染（HIV）的人，一种与 HIV 相当的免疫抑制性疾病，当他们的外周血中升高的免疫球蛋白 κ 和 λ 游离轻链（FLC）时，发生淋巴瘤的机会更高。
本系统评价的目的是监测 PTLD 患者中相关 B 淋巴瘤细胞。为了找到 2000 年 1 月 1 日至 2022 年 1 月 9 日期间发表的相关研究，两名独立研究人员进行了检索（MT，AJ）。通过 PubMed 在 MEDLINE、Ovid 上的 EMBASESTM、Cochrane 图书馆和 Trip 进行了英语文献检索。除了 Magiran 和 SID，我们还在韩国医学数据库和 LILACS 中搜索了其他语言发表的文献。搜索策略中使用了 sFLC 或 PTLD、移植或电泳等术语。
共选择了 174 项研究。在分析其与所需标准的对应关系后，对五项研究进行了最终评价。本手稿介绍了 sFLC 在 PTLD 中的临床应用的潜在益处的最新发现。虽然初步结果看起来很有希望，但唯一一致的结果是，在移植后两年内预测早期发作的 PTLD，这是一种可用于诊断该疾病的生物标志物。
因此，已经使用 sFLC 预测了 PTLD。迄今为止，结果存在矛盾。未来的研究可以包括评估移植受者中 sFLC 的数量及其质量。除了移植后的 PTLD 和并发症外，sFLC 还可能为其他疾病提供深入了解。为了确认 sFLC 的有效性，需要进行更多的研究。
